A study to evaluate the processing by the body and safety of pralsetinib in participants with hepatic impairment compared to healthy participants

A Phase I, Open-Label, Single-Dose Study to Evaluate the Pharmacokinetics and Safety of Pralsetinib in Subjects With Moderate or Severe Hepatic Impairment Compared to Healthy Subjects

  • Hepatic Insufficiency
Trial Status:

Not yet recruiting

This trial runs in
Cities
Trial Identifier:

GP43163

      Show trial locations

      The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

      The below information is taken directly from the publicly available website ClinicalTrials.gov within a week of any updates, and has not been edited.

      Results Disclaimer

      Trial Summary

      The purpose of this study is to measure how much of the study drug gets into the blood stream and how long it takes the body to get rid of it in participants with healthy livers compared to participants with moderate or severe liver impairment. In addition, this study will evaluate the safety and tolerability of the study drug in participants with healthy livers and participants with moderate or severe liver impairment. Information about any side effects that may occur will also be collected.

      GP43163 Trial Identifier
      Male and Female Gender
      18 to 74 Years Age
      Yes Healthy Volunteers

      Who can participate?
      Subjects aged between 18 to 74 years who are healthy, or have liver impairment.

      What does the study involve? (what interventions will be compared, will all participants receive the same treatment, what measurements will be taken)

      During this study, participants have two visits, including a screening visit up to 34 days before the start of the study, and a stay in the study site lasting 10 days and 9 nights. The total duration of  participation in the study will be about 10 days. In this study, the study doctor, and the sponsor will know the drugs and the doses that are given. Participants will be given a single oral (by mouth) dose of 200 mg pralsetinib given as 2 capsules on Day 1 given in the morning with one cup of water after an overnight fast (no food or drink other than water) of at least 8 hours. Then, it will be required to remain fasting for at least 2 hours after dosing (a total fast of at least 10 hours). One will not be allowed to drink water (except for the water given with dosing) from 1 hour before dosing to 2 hours after taking the capsules.

      This study requires that a blood sample be obtained that may be used for additional research involving genetic analysis of blood. If participants do not wish to have this sample collected, will not be permitted to participate in this study. There is an additional research that may involve long‑term storage for future analysis of blood for the Research Biosample Repository (RBR). Participants will be asked to sign a separate section of the informed consent for this additional research. If participants do not wish to participate in this additional research, the participation in this main research study will not be affected.

      What are the possible benefits and risks of participating?
      Participation in this study is purely for research purposes, and will not improve ones health or treat any medical problems. One may benefit by having physical examinations. The results of laboratory tests done at the screening visit will be made available upon request. However, if  disqualified for study participation by other screening procedures, some laboratory tests may not be conducted.

      Participants may have side effects from the drugs or procedures used in this study. Side effects can be mild to severe and even life threatening or fatal, and they can vary from person to person. Talk to the study doctor right away if one experiences any side effects during the study. There may be a risk in exposing an unborn child to study drug, and all risks are not known at this time. Women and men must take precautions to avoid exposing an unborn child to study drug, as described in Section 1.6. If participants are pregnant, become pregnant, or are currently breastfeeding, one cannot take part in this study.

      Where is the study run from?
      United States

      When is the study starting and how long is it expected to run for?
      November 2021 to June 2022

      Who is funding the study?
      Genentech, Inc

      Who is the main contact?
      global-roche-genentech-trials@gene.com

      Trial Summary

      The purpose of this study is to measure how much of the study drug gets into the blood stream and how long it takes the body to get rid of it in participants with healthy livers compared to participants with moderate or severe liver impairment. In addition, this study will evaluate the safety and tolerability of the study drug in participants with healthy livers and participants with moderate or severe liver impairment. Information about any side effects that may occur will also be collected.

      GP43163 Trial Identifier
      Pralsetinib Treatments

      Eligibility Criteria

      Male and Female Gender
      18 to 74 Years Age
      Yes Healthy Volunteers

      For the latest version of this information please go to www.forpatients.roche.com

       

      Related Trials

      Use our search to find other trials on Genentech Clinical Trials in related disease areas.

      Hepatic Insufficiency

      About Clinical Research

      What is a clinical trial? Why should I consider taking part in a clinical trial? And why does Genentech conduct clinical trials?

      Find out now